Top Page
iSpecimen
(NASDAQ:ISPC)
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
iSpecimen Business Overview & Revenue Model
iSpecimen Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35M | 9.29M | 9.93M | 10.40M | 11.14M | 8.18M |
| Gross Profit | 722.54K | 3.99M | 5.11M | 5.65M | 5.89M | 4.60M |
| EBITDA | -9.47M | -12.73M | -8.80M | -8.80M | -5.86M | -1.74M |
| Net Income | -11.53M | -12.50M | -11.10M | -10.25M | -8.96M | -4.65M |
Balance Sheet | ||||||
| Total Assets | 9.00M | 9.35M | 15.82M | 24.62M | 35.72M | 6.21M |
| Cash, Cash Equivalents and Short-Term Investments | 2.78M | 1.88M | 5.01M | 15.31M | 27.74M | 695.91K |
| Total Debt | 281.44K | 312.17K | 196.24K | 185.85K | 3.42M | 12.77M |
| Total Liabilities | 5.92M | 6.04M | 6.08M | 4.31M | 5.93M | 33.49M |
| Stockholders Equity | 3.07M | 3.31M | 9.74M | 20.31M | 29.79M | -27.28M |
Cash Flow | ||||||
| Free Cash Flow | -6.79M | -8.30M | -10.55M | -9.01M | -11.71M | -1.39M |
| Operating Cash Flow | -6.76M | -8.26M | -5.81M | -5.82M | -10.67M | -288.38K |
| Investing Cash Flow | -1.07M | 1.98M | -7.23M | -3.19M | -1.04M | -1.10M |
| Financing Cash Flow | 8.86M | 5.82M | 70.89K | -3.42M | 38.75M | 2.03M |
iSpecimen Technical Analysis
iSpecimen Risk Analysis
iSpecimen Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.24M | ― | ― | ― | ― | ― | |
46 Neutral | $9.56M | -0.43 | -223.45% | ― | 3.26% | 65.96% | |
45 Neutral | $5.71M | -0.05 | -245.18% | ― | -27.66% | 13.18% | |
41 Neutral | $3.33M | -0.04 | -296.20% | ― | -67.73% | 58.35% |
iSpecimen Corporate Events
iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders on December 31, 2025, but the meeting was adjourned twice—first on December 31 and again when reconvened on January 23, 2026—because the company failed to achieve a quorum of shareholders. The company now plans to reconvene the delayed 2025 Annual Meeting on February 13, 2026, with the record date remaining November 3, 2025, highlighting ongoing challenges in securing sufficient shareholder participation to vote on proxy proposals and finalize annual governance matters.
The most recent analyst rating on (ISPC) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On December 31, 2025, iSpecimen Inc. convened its 2025 annual meeting of stockholders but adjourned it after failing to achieve a quorum of shareholders needed to conduct business on the proposals previously circulated. The company plans to reconvene the annual meeting on January 23, 2026, maintaining November 3, 2025 as the record date, signaling an effort to secure sufficient shareholder participation to move forward with its proposed agenda.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.28 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On December 31, 2025, iSpecimen Inc. completed a private placement of its Series C Convertible Non-Voting Preferred Stock and entered into a Consulting Agreement with IR Agency LLC to provide marketing, advertising, and investor communications services for an initial four-month term starting the same day. The consultant, acting as an independent contractor on a non-exclusive basis, received a $2 million cash fee funded from the private placement proceeds, and the agreement—which includes standard contractual protections and can be terminated at any time by either party—signals iSpecimen’s effort to strengthen its market visibility and investor outreach without engaging in securities solicitation activities.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.28 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On December 30, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors to issue 6,875 shares of newly created Series C Convertible Non-Voting Preferred Stock, each with a stated value of $1,000 and sold at $800 per share, and on December 31, 2025 closed the transaction for aggregate gross proceeds of $5.5 million. The Series C preferred shares, which were structured to rank senior to common stock in dividends and liquidation and carry no general voting rights, are convertible into common shares at 85% of the prior trading day’s closing price, subject to a floor price, and were sold in a private placement under Regulation D, with iSpecimen granting investors registration rights for the resale of conversion shares and appointing E.F. Hutton & Co. as exclusive placement agent, a move that strengthens the company’s capital position but introduces potential future equity dilution for existing shareholders.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.28 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On November 28, 2025, iSpecimen Inc. received confirmation from the Nasdaq Listing Qualifications Staff that it now meets the continued listing requirements under Nasdaq Listing Rules. Previously, on June 4, 2025, the company was notified of non-compliance with the minimum stockholders’ equity, market value of listed securities, or net income requirements. However, as of September 30, 2025, iSpecimen reported stockholders’ equity of $3,072,711, regaining compliance and closing the matter.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.40 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On November 19, 2025, iSpecimen Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days, putting the company out of compliance with Nasdaq’s listing rules. The company has until May 18, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. If compliance is not regained, iSpecimen may seek an additional compliance period or face potential delisting, with options including a reverse stock split to address the deficiency.
The most recent analyst rating on (ISPC) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On November 7, 2025, iSpecimen Inc. announced significant leadership changes with the appointment of Ms. Katharyn Field as Chief Executive Officer, Secretary, and Treasurer, succeeding Mr. Robert Bradley Lim who resigned from these roles and the Board. Ms. Field, who has been serving as President since February 2025, brings extensive experience in strategy consulting and executive leadership, particularly in the cannabis industry. Additionally, Mr. Arphing (Tommy) Lee was appointed as an independent director, joining the Audit and Nominating and Corporate Governance Committees. The company emphasized that these leadership changes are not expected to disrupt operations, and the Board remains focused on executing the company’s objectives.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On October 30, 2025, iSpecimen Inc. held a special meeting of stockholders to vote on several key proposals. The company successfully approved a reverse stock split, an increase in authorized shares, and amendments related to private financing transactions and convertible securities, all of which are aimed at enhancing its financial flexibility and compliance with Nasdaq rules.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.